Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
looks like there's a problem with LSE again and RNSs very slow to appear here.
Enables capture and rapid transfer of medical images from remote locations to the Bleepa platform over mobile networks
· Images acquired in remote settings can be instantly reviewed by specialists in other locations, connected via the Bleepa platform for instant case discussion, enabling point of care patient management
· Multiple commercial opportunities including veterinary, international markets and the military
London, 23 September 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that following the success of the store and forward concept delivered in partnership with the equine division of CVS Group plc it is officially launching Bleepa Box, a specialist tool to enable image transfer from remote settings to the Bleepa platform.
Bleepa Box is a small tablet device that connects to imaging machines in order to securely push images to Bleepa over a mobile network from remote locations. Crucially Bleepa does not need WiFi access. Images are downloaded from the imaging machine onto the Bleepa Box then automatically pushed to Bleepa. The clinician who acquired the images can then review the images directly on the Bleepa Box and can make onward referrals or start a conversation with a specialist for input on the case whilst still in the remote location. This enables rapid decision making and treatment of the patient within that first visit, at the point of care, for cases that previously would have required transfer to treatment centres for imaging and management. This enables new capabilities around remote investigation and patient management, allowing patient imaging to be carried out and discussed in settings that were previously unreachable for traditional care models.
In addition to the veterinary imaging market which is growing at a compound annual growth rate of 6.7% and is expected to be worth an estimated £2.24bn in the UK1 by 2025, Bleepa Box's remote image capabilities are relevant to a number of other significant commercial opportunities including the delivery of rural imaging for TB screening services in India, as announced in our MOU with Qure.ai on 14 September 2021 and routes to support the military infield market.
Dr Tom Oakley, CEO of Feedback, said: "This technology was a solution created, designed and launched to support the work we are doing in the veterinary market with CVS and we are now taking the steps to formally build a brand around this capability. Imaging of horses is typically done in remote stables without WiFi, but there is often the need for timely advice and guidance by specialists whilst the vet is with the animal. We developed the store and forward technology that enables them to analyse and treat animals on site, which reduces the vet's workload, travel time and is certainly better for the animal... cont
Pt2
However, clearly there are other markets that have this requirement and formally branding the solution as Bleepa Box enables us to build a market around this capability across a range of industries. We anticipate that the product can be sold in combination with Bleepa or potentially as a standalone offering to facilitate image sharing to other third-party systems such as PACS."
I wonder how beneficial this would be to the emergency services at major incidents.
For 13 years I was involved in attending/dealing with major road accidents, where sometimes persons involved were trapped for several hours (The Selby Rail Crash 2001).
Although Paramedics are very well trained, specialist advice re trauma injuries could be invaluable in many situations.
Feedback is still very much under the radar, shown by a single trade and no SP increase as I post.
I would increase my holdings, but although I am very positive re this company, I feel that my risk judgement equals my present investment.
Just looking at the CVS Group website. It's a big outfit and financially very strong. A good partner to have with potential to extend the Bleepa contract further.
Over 500 practices
More than 1,900 vets
In excess of 2,500 nurses
Year end 2021 – Revenue £510.1m
Financial Highlights
Revenue increased by 19.2%, to £510.1m from £427.8m, with strong group like-for-like1 growth of 17.4% benefitting from favourable market dynamics and a continued focus on providing high quality care to our clients and their animals
The Group delivered adjusted EBITDA2 growth of 37.3%, to £97.5m from £71.0m, through an increase in revenue across all divisions and effective management of costs
Profit before income tax increased by 234.3% to £33.1m from £9.9m
Leverage5 fell to 0.68x from 1.14x as a result of strong EBITDA growth and reduction in net debt
Cash generated from operations decreased to £80.3m from £94.8m despite the increase in adjusted EBITDA, due to VAT and taxes deferred in the prior year due to COVID-19, paid in the current year